Back

Comparison of two anthracycline regimens for treatment of breast cancer and the incidence of cardiac injury

2 September 2024 (10:00 - 10:40)
Organised by: Logo
Congress Presentation Part of: Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Nichanan Osataphan

Chiang Mai University, Chiang Mai (Thailand)

5 More presentations in this session

Presentation thumbnail
Prospective screening and proposed treatment algorithm for immune checkpoint inhibitor induced myositis in neoadjuvant-treated rectal cancer patients: data from the phase II CHINOREC trial
Doctor R. Zirnbauer (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
Doctor S. Lingamsetty (Khammam, IN)
Abstract Slides Video
Presentation thumbnail
Anthracycline-induced arterial toxicity: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography
Doctor S. Rankin (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab
Doctor N. Espinola-Zavaleta (Mexico City, MX) Doctor E. Guerra (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence, definitions and outcomes of anthracycline induced subclinical and clinical left ventricular dysfunction: a systematic review and meta-analysis
Doctor N. Farooqui (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention

The Event

Event poster

ESC Congress 2024

2 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.
thumbnail
Congress Presentation
Decoding chemotherapy-related cardiac dysfunction prediction: left ventricular strain imaging or HFA-ICOS score?
thumbnail
Congress Presentation
Prospective study of impact of cardiotoxic chemotherapy protocol and frequency on arrhythmia occurrence in patients with breast cancer

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources